ADL Amdl,

AMDL Reports 2003 Third Quarter Financial Results TUSTIN, Calif., Nov. 19 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL; Berlin, Frankfurt), developer and marketer of tests for the early detection of cancer and other serious diseases, recently reported results for the three and nine months ended September 30, 2003. Product revenues for the three months ended September 30, 2003 totaled $73,764, a 255 percent increase compared to product revenues of $20,748 for the three months ended September 30, 2002. "AMDL's cash position currently is approximately $2 million, putting the Company in a strong financial posture as we await a decision from the U.S. Food & Drug Administration on our filing for clearance to market our DR-70(R) non-invasive cancer blood test," said Gary L. Dreher, President. Net loss from operations for the third quarter in 2003 was $(819,000), or ($0.06) per share, compared to the net loss from operations of $(1.14 million), or ($0.06) per share, for the 2002 period. For the nine months ended September 30, 2003, product revenues totaled $198,968, a 110 percent increase compared to product revenues of $94,554 for the nine months ended September 30, 2002. Net loss from operations for the nine months ended September 30, 2003 was $(2.33 million), or ($0.21) per share, significantly improved from the net loss from operations of $(3.05 million), or ($0.36) per share, for the comparable period in 2002. During the nine months ended September 30, 2003, AMDL expensed $479,318, or ($0.05) per share, of non-cash interest expense in connection with its recent private placement offerings. About AMDL AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, is a theranostics company, involved in the detection and treatment of the same disease, cancer. AMDL is the inventor, developer and worldwide marketer through exclusive distribution agreements of the DR-70(R) non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. In a study published in the Journal of Immunoassay (1998, vol. 19, pp 63-72) DR-70(R) was shown to detect at least 13 different types of cancer (lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, pancreatic) although the sample size for 9 of the cancers was not statistically significant. Clinical trials of DR-70(R) have been conducted in Canada, China, Germany, Taiwan and Turkey. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells. More information about AMDL and its additional products can be obtained at http://www.amdlcorporate.com/ . Forward-Looking Statements Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release. DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdlcorporate.com/

Copyright